news
New CAR-T cell therapy targets aggressive brain tumors
Researchers at Nature News found that an engineered CAR-T cell therapy, targeting the GPNMB protein, effectively shrank glioblastoma tumors in preclinical models. This dual-targeting approach could offer a new way to fight one of the most aggressive brain cancers. The study was led by Dr. John Smith.
Researchers at Nature News found that an engineered CAR-T cell therapy, targeting the GPNMB protein, effectively shrank glioblastoma tumors in preclinical models. This dual-targeting approach could offer a new way to fight one of the most aggressive brain cancers. The study was led by Dr. John Smith.
The architecture take
CAR-T is moving beyond blood cancers, and this dual-targeting approach for glioblastoma is a big deal. For folks with this diagnosis, it's not just a new drug, it's a re-engineering of the body's own defense system to ID and wipe out cancer cells.